← Browse by Condition
Medical Condition

interstitial lung diseases

Total Trials
3
Recruiting Now
3
Trial Phases
Various

Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.

Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.

Frequently Asked Questions — interstitial lung diseases Clinical Trials

How many clinical trials are currently recruiting for interstitial lung diseases?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for interstitial lung diseases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for interstitial lung diseases?
interstitial lung diseases research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a interstitial lung diseases clinical trial?
Eligibility criteria for interstitial lung diseases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Institut National de la Santé Et de la Recherche Médicale, France 1 trial
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial
IRCCS San Raffaele 1 trial

Recruiting Clinical Trials

NCT06036719
Recruiting
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
Enrollment
3,000 pts
Location
France
Sponsor
Institut National de la Santé ...
View Trial →
NCT06068647
Recruiting
Ultrasound and Respiratory Physiological Signals in Lung Diseases
Enrollment
25 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT06537934
Recruiting
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
Enrollment
123 pts
Location
Italy
Sponsor
IRCCS San Raffaele
View Trial →

Related Conditions

interstitial lung disease (1) interstitial pneumonia (1) chronic obstructive pulmonary disease (1) emphysema or copd (1) ultrasonography (1) ultrasound imaging (1) ultrasound (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology